382150 fundamentals
Key facts
About
Oncocross Co., Ltd. engages in conducting joint research on new drugs with several domestic and foreign pharmaceutical companies. It provides a new approach to new drug development by sharing the analysis results using AI new drug development platform. The company was founded by Yi-Rang Kim on June 22, 2015 and is headquartered in Seoul, South Korea.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
−3,900.0%
−3,000.0%
−2,100.0%
−1,200.0%
−300.0%
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
−2.40 B
−1.60 B
−800.00 M
0.00
800.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Dividends
Dividend yield, history and sustainability
No dividends
382150 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company